文献速递妇科

复发性或转移性宫颈癌二线治疗的社区肿瘤学分析

Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
PubMed 文献 · Gynecol Oncol · 2021-03-17

该观察性研究纳入2014至2019年美国社区肿瘤网络中130例一线治疗失败后启动二线系统治疗的复发性或转移性宫颈癌患者,描述其患者特征、治疗模式及临床结局。二线治疗方案异质性大,以细胞毒性单药最常见(46%),中位总生存期仅9.1个月,各方案间无显著差异,提示该领域缺乏标准治疗且亟需新选择。

要点

  • 二线治疗以细胞毒性单药最常见(46%),方案异质性大,无明确标准治疗。
  • 启动二线治疗后中位总生存期仅9.1个月(95%CI 7.2-12.2)。
  • 按二线治疗方案分层,临床结局无显著差异。

核心结论

  • 复发性或转移性宫颈癌二线治疗模式异质,无明确标准治疗,各方案总生存期均较短,亟需新的有效治疗选择。

研究设计与样本

  • 观察性研究,基于美国肿瘤网络电子健康记录,纳入2014至2019年一线系统治疗失败后启动二线系统治疗的复发性或转移性宫颈癌患者130例,平均年龄53岁。

主要发现

  • 二线治疗方案中细胞毒性单药60例(46%),联合治疗45例(35%),帕博利珠单抗单药19例(15%),贝伐珠单抗单药6例(5%)。
  • 启动二线治疗后中位总生存期为9.1个月(95%CI 7.2-12.2)。
  • 中位治疗至停药时间为2.8个月(95%CI 2.5-3.3),中位至首次后续治疗时间为4.9个月(95%CI 4.2-5.7)。
  • 按二线治疗方案分层,各结局无显著差异。

临床怎么用

  • 临床实践中应认识到复发性或转移性宫颈癌二线治疗缺乏标准方案,现有方案生存获益有限,可考虑临床试验或新药治疗。

局限性

  • 为观察性研究,样本量130例,来源于美国社区肿瘤网络,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is no standard systemic treatment for recurrent or metastatic cervical cancer (r/mCC) after failure of first-line (1L) therapy. This study characterizes the patient experience, treatment patterns, and clinical outcomes of patients who initiated second-line (2L) therapy for r/mCC in a US community oncology setting. METHODS: This is an observational study of cervical cancer patients who failed 1L systemic treatment for r/mCC and initiated 2L systemic therapy between 2014 and 2019 within the US Oncology Network (USON). USON's electronic health records were used to identify eligible patients and abstract data. Overall survival (OS), time to treatment discontinuation (TTD), and time to first subsequent treatment (TFST) were estimated using Kaplan-Meier methods. RESULTS: A total of 130 patients were identified (mean age 53 years). Over 60% of patients had Eastern Cooperative Oncology Group score of 0-1. Cytotoxic monotherapy was the most frequently prescribed regimen (N = 60, 46%) in 2L, followed by combination therapies (N = 45, 35%), pembrolizumab monotherapy (N = 19, 15%), and bevacizumab monotherapy (N = 6, 5%). Median OS was 9.1 months (95% CI: 7.2-12.2) after initiation of 2L therapy. Median TTD was 2.8 months (95% CI: 2.5-3.3), and median TFST was 4.9 months (95% CI: 4.2-5.7). No significant difference in outcomes was found when stratified by 2L treatments. CONCLUSIONS: The observed heterogeneity in 2L r/mCC therapy suggests no clear standard-of-care in this setting. Additionally, short duration of OS observed was consistent across 2L regimens. New, effective treatment options in this setting are needed.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Alholm Z, Monk BJ, Ting J, et al. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis. Gynecol Oncol. 2021. PMID: 33741208. doi:10.1016/j.ygyno.2021.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。